PMID- 35116944
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220501
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 8
IP  - 5
DP  - 2019 Sep
TI  - Comparison of liver function and safety in hepatocellular cancer patients treated 
      with DEB-TACE and cTACE: a multi-center, retrospective cohort study.
PG  - 1950-1964
LID - 10.21037/tcr.2019.09.15 [doi]
AB  - BACKGROUND: This study aimed to compare the live function change and adverse 
      events (AEs) between drug-eluting beads (DEB) transarterial chemoembolization 
      (TACE) with CalliSpheres((R)) microspheres (CSM) and conventional TACE (cTACE) in 
      treating hepatocellular carcinoma (HCC) patients. METHODS: Three hundred and 
      thirty-five HCC patients underwent DEB-TACE with CSM (n=171, DEB-TACE group) or 
      cTACE (n=164, cTACE group) were consecutively enrolled in this multi-center, 
      retrospective cohort study. Liver function indexes were reviewed before treatment 
      (W0), at 1 week (W1) and 1 month (M1) post treatment. Moreover, AEs during 
      operation and hospitalization were retrieved as well. RESULTS: The changes of 
      albumin (ALB) [-3.55 (-6.25 to -0.43) vs. -2.20 (-4.63-0.00), P=0.043] and total 
      protein (TP) [-4.62 (-10.18-0.43) vs. -2.50 (-7.08-1.08), P=0.013] from W1 to W0 
      were lower in DEB-TACE group compared to cTACE group, while no difference was 
      observed referring to the change of alanine aminotransferase (ALT) (P=0.494), 
      aspartate aminotransferase (AST) (P=0.747), alkaline phosphatase (ALP) (P=0.895), 
      total bilirubin (TBIL) (P=0.059), total bile acid (TBA) (P=0.491) from W1 to W0. 
      And the changes of these seven indexes from M1 to W0 were all similar between 
      DEB-TACE group and cTACE group (all P>0.05). Besides, the occurrence of pain 
      during treatment (19.3% vs. 11.0%, P=0.034) and the occurrence of fever during 
      hospitalization (18.1% vs. 9.1%, P=0.017) were both increased in DEB-TACE group 
      compared to cTACE group. CONCLUSIONS: DEB-TACE with CSM is non-inferior to cTACE 
      in terms of liver function change, while DEB-TACE with CSM leads to higher 
      incidences of pain and fever.
CI  - 2019 Translational Cancer Research. All rights reserved.
FAU - Xiang, Hua
AU  - Xiang H
AD  - Department of Intervention, Hunan Provincial People's Hospital, Changsha 410005, 
      China.
FAU - Xiong, Bin
AU  - Xiong B
AD  - Department of Interventional Radiology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan 430022, China.
FAU - Li, Haiping
AU  - Li H
AD  - Department of Radiology, Xiangya Hospital, Central South University, Changsha 
      410008, China.
FAU - Zhao, Chang
AU  - Zhao C
AD  - Department of Interventional Therapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, China.
FAU - Zhang, Zishu
AU  - Zhang Z
AD  - Department of Radiology, The Second Xiangya Hospital of Central South University, 
      Changsha 410011, China.
FAU - Ma, Cong
AU  - Ma C
AD  - Department of Radiology, The Second Xiangya Hospital of Central South University, 
      Changsha 410011, China.
FAU - Zheng, Chuansheng
AU  - Zheng C
AD  - Department of Interventional Radiology, Union Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan 430022, China.
FAU - Luo, Chao
AU  - Luo C
AD  - Department of Radiology, Wuhan General Hospital of Guangzhou Military, Wuhan, 
      China.
FAU - Qiu, Huaiming
AU  - Qiu H
AD  - Department of Radiology, Wuhan General Hospital of Guangzhou Military, Wuhan, 
      China.
FAU - Yao, Yuanhui
AU  - Yao Y
AD  - Department of Intervention, Hunan Provincial People's Hospital, Changsha 410005, 
      China.
FAU - Hu, Hongyao
AU  - Hu H
AD  - Department of Radiology, Renmin Hospital of Wuhan University, Hubei General 
      Hospital, Wuhan 430070, China.
FAU - Zhao, Hui
AU  - Zhao H
AD  - Department of Radiology, Renmin Hospital of Wuhan University, Hubei General 
      Hospital, Wuhan 430070, China.
FAU - Long, Qingyun
AU  - Long Q
AD  - Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, 
      China.
FAU - Zhou, Jun
AU  - Zhou J
AD  - Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, 
      China.
FAU - Chen, Changyong
AU  - Chen C
AD  - Department of Radiology, Xiangya Hospital, Central South University, Changsha 
      410008, China.
FAU - Ma, Yilong
AU  - Ma Y
AD  - Department of Interventional Therapy, Affiliated Tumor Hospital of Guangxi 
      Medical University, Nanning 530021, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC8799233
OTO - NOTNLM
OT  - CalliSpheres(R) microspheres (CSM)
OT  - conventional transarterial chemoembolization (cTACE)
OT  - drug-eluting bead transarterial chemoembolization (DEB-TACE)
OT  - hepatocellular carcinoma (HCC)
OT  - liver function
OT  - safety
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tcr.2019.09.15). The authors have 
      no conflicts of interest to declare.
EDAT- 2019/09/01 00:00
MHDA- 2019/09/01 00:01
PMCR- 2019/09/01
CRDT- 2022/02/04 05:50
PHST- 2019/01/03 00:00 [received]
PHST- 2019/08/23 00:00 [accepted]
PHST- 2022/02/04 05:50 [entrez]
PHST- 2019/09/01 00:00 [pubmed]
PHST- 2019/09/01 00:01 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - tcr-08-05-1950 [pii]
AID - 10.21037/tcr.2019.09.15 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2019 Sep;8(5):1950-1964. doi: 10.21037/tcr.2019.09.15.